Le Lézard
Classified in: Health
Subject: LAW

U.S. District Court Rules in Favor of GOLO, the Health and Wellness Solutions Company, and Dismisses Class Action Lawsuit


The dismissal comes early on in its procedural status and reflects GOLO's consistent view that the lawsuit was without merit.

NEWARK, Del., Jan. 18, 2024 /PRNewswire-PRWeb/ -- Judge Dale A. Drozd from the U.S. District Court for the Eastern District of California recently issued a nine-page decision granting GOLO's motion to dismiss a false advertising class action lawsuit filed against the company in 2021 in the case, Bubak v. GOLO, LLC, US District Court for the Eastern District of California, 1:21-cv-00492-DAD-AC.

"We are very pleased with this result and the Court's decision here," said Chris Lundin, GOLO's CEO.

The dismissal comes early on in its procedural status and reflects GOLO's consistent view that the lawsuit was without merit.

"We are very pleased with this result and the Court's decision here," said Chris Lundin, GOLO's CEO. "GOLO has always been and remains committed to providing our customers with safe, effective, and sustainable solutions to their health, wellness, and weight loss needs."

"There has been some misleading information online about this case, and the Court's ruling for GOLO should provide clarity to the record," added Keith Walter, GOLO's General Counsel. "This decision also validates GOLO's position from the outset that this class action lawsuit should have never been filed, and I am glad to see it concluded with the Judge applying recent Ninth Circuit precedent."

About GOLO:
GOLO has provided health and wellness solutions since 2013 and has over 4 million customers. Headquartered in Newark, Delaware, GOLO has distribution centers in Wilmington, Delaware, Las Vegas, Nevada, and Dallas, Texas, and employs over 130 people.

GOLO's flagship products are the GOLO for Life® Plan, a servings-based healthy eating program, and the patented Release® dietary supplement. The health benefits of GOLO and Release have been confirmed in clinical studies and there are over 100 studies on the safety and efficacy of the ingredients in Release.

The Release supplement contains seven plant-based ingredients and three minerals. Key ingredients in Release have been extensively studied and shown to improve metabolic efficiency, help balance key hormones associated with weight, enhance the immune system, increase energy, and reduce stress and mental fatigue, common factors associated with dieting. Release contains no caffeine or stimulants.

GOLO's dual action and back-to-basics holistic approach to weight loss and wellness focuses on metabolic health, sustainable behavior and lifestyle change, resulting in steady weight loss. GOLO provides a safe, affordable, and effective total wellness solution.

GOLO encourages and empowers people to embrace healthy lifestyle changes, proper nutrition, and emotional well-being instead of quick-fix drugs or fad diets. By adopting a holistic approach to weight management, GOLO can help individuals achieve lasting results and lead healthier, happier lives.

In 2023, GOLO donated over $350,000 to US charities, including The Food Bank of Delaware, Special Olympics of Delaware and Nevada, and Ronald McDonald House Charities of Delaware. The company also delivered over 215,000 balanced, nutrient dense GOLO Foods meals to food banks and food pantries in New York, Delaware, New Jersey, Philadelphia, Nevada, and Texas. The company aims to distribute over 1 million meals this year to help address hunger and promote the health benefits of consuming nutrient-dense foods.

For more information on GOLO, go to golo.com or visit the GOLO Newsroom.

Media Contact

Marvin Mack, GOLO LLC, 302-455-2167, mack@golo.com, www.golo.com 

SOURCE GOLO LLC


These press releases may also interest you

at 21:07
Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010...

at 20:51
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...

at 20:30
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...

at 20:05
CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under...

at 19:42
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to...

at 18:54
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...



News published on and distributed by: